Yanbo Zheng

680 total citations
40 papers, 308 citations indexed

About

Yanbo Zheng is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Yanbo Zheng has authored 40 papers receiving a total of 308 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 12 papers in Oncology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Yanbo Zheng's work include Microtubule and mitosis dynamics (6 papers), Cancer therapeutics and mechanisms (5 papers) and Cancer-related Molecular Pathways (5 papers). Yanbo Zheng is often cited by papers focused on Microtubule and mitosis dynamics (6 papers), Cancer therapeutics and mechanisms (5 papers) and Cancer-related Molecular Pathways (5 papers). Yanbo Zheng collaborates with scholars based in China and Australia. Yanbo Zheng's co-authors include Jianhua Gong, Yong‐Su Zhen, Xiujun Liu, Yi Li, Tao Wang, Shuyi Si, Xing Lv, Lijun Yang, Shuying Wu and Liang Li and has published in prestigious journals such as PLoS ONE, Scientific Reports and Biochemical and Biophysical Research Communications.

In The Last Decade

Yanbo Zheng

39 papers receiving 306 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yanbo Zheng China 11 169 86 69 56 35 40 308
Qunying Wu China 10 243 1.4× 58 0.7× 100 1.4× 35 0.6× 45 1.3× 15 351
Dongdong Luo China 11 219 1.3× 121 1.4× 121 1.8× 67 1.2× 18 0.5× 27 387
Saeed Salehin Akhand United States 7 240 1.4× 85 1.0× 49 0.7× 37 0.7× 35 1.0× 12 320
Nathalia Meireles Da Costa Brazil 14 283 1.7× 99 1.2× 135 2.0× 87 1.6× 24 0.7× 30 467
Katherine T. Ostapoff United States 10 146 0.9× 197 2.3× 87 1.3× 55 1.0× 26 0.7× 18 361
Ruoxuan Hei China 7 150 0.9× 126 1.5× 55 0.8× 86 1.5× 22 0.6× 14 292
Carolina Hassibe Thomé Brazil 14 308 1.8× 112 1.3× 129 1.9× 43 0.8× 25 0.7× 30 482
Stanislav Drápela Czechia 11 235 1.4× 118 1.4× 122 1.8× 43 0.8× 33 0.9× 19 385
Rukh Yusuf United States 4 243 1.4× 163 1.9× 92 1.3× 35 0.6× 15 0.4× 8 422
Loreley Calvet France 7 134 0.8× 107 1.2× 54 0.8× 100 1.8× 17 0.5× 11 319

Countries citing papers authored by Yanbo Zheng

Since Specialization
Citations

This map shows the geographic impact of Yanbo Zheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yanbo Zheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yanbo Zheng more than expected).

Fields of papers citing papers by Yanbo Zheng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yanbo Zheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yanbo Zheng. The network helps show where Yanbo Zheng may publish in the future.

Co-authorship network of co-authors of Yanbo Zheng

This figure shows the co-authorship network connecting the top 25 collaborators of Yanbo Zheng. A scholar is included among the top collaborators of Yanbo Zheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yanbo Zheng. Yanbo Zheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Jiang, Bin, Jizhou Wu, Huijuan Song, et al.. (2025). Identification of selenium-containing benzamides as potent microtubule-targeting antitumor agents. Bioorganic Chemistry. 159. 108355–108355. 2 indexed citations
2.
Zhu, Xianyu, Lingli Gao, Yanbo Zheng, et al.. (2025). Porous Fe/Cu Nanoreactor with Dual Insurance Design for Precision Chemotherapy and Chemodynamic Therapy. Advanced Healthcare Materials. 14(16). e2405229–e2405229. 1 indexed citations
3.
Li, Yi, et al.. (2024). The triple combination DBDx alleviates cytokine storm and related lung injury. International Immunopharmacology. 143(Pt 2). 113431–113431.
4.
Lv, Xing, Xiaoxue Li, Hai Shang, et al.. (2024). Dual inhibition of topoisomerase II and microtubule of podophyllotoxin derivative 5p overcomes cancer multidrug resistance. European Journal of Pharmacology. 983. 176968–176968. 3 indexed citations
5.
Li, Shuxuan, Yujing Li, Yonghua Liu, et al.. (2024). Novel pyridazinone derivatives bind to KSRP: Synthesis, anti-tumor biological evaluations and modelling insights. European Journal of Medicinal Chemistry. 278. 116811–116811. 1 indexed citations
6.
Zhang, Junyi, et al.. (2023). mPEG-PDLLA polymeric micelles loading a novel pyridazinone derivative IMB5036 for improving anti-tumor activity in hepatocellular carcinoma. Journal of Drug Delivery Science and Technology. 90. 105101–105101. 2 indexed citations
7.
Hong, Hanyu, Yujing Li, Junyi Zhang, et al.. (2023). An albumin-binding lidamycin prodrug for efficient targeted cancer therapy. Journal of Drug Delivery Science and Technology. 91. 105213–105213. 1 indexed citations
8.
9.
Lv, Xing, et al.. (2022). IMB5036, a novel pyridazinone compound, inhibits hepatocellular carcinoma growth and metastasis. Investigational New Drugs. 40(3). 487–496. 5 indexed citations
10.
Zheng, Yanbo, Jianhua Gong, & Yong‐Su Zhen. (2020). Focal adhesion kinase is activated by microtubule‐depolymerizing agents and regulates membrane blebbing in human endothelial cells. Journal of Cellular and Molecular Medicine. 24(13). 7228–7238. 6 indexed citations
11.
Wang, Tao, et al.. (2019). LINC00467 promotes cell proliferation and metastasis by binding with IGF2BP3 to enhance the mRNA stability of TRAF5 in hepatocellular carcinoma. The Journal of Gene Medicine. 22(3). e3134–e3134. 36 indexed citations
12.
Tan, Tan, et al.. (2019). Deletion of INMAP postpones mitotic exit and induces apoptosis by disabling the formation of mitotic spindle. Biochemical and Biophysical Research Communications. 518(1). 19–25. 1 indexed citations
13.
14.
Zheng, Yanbo, et al.. (2016). A CD13‐targeting peptide integrated protein inhibits human liver cancer growth by killing cancer stem cells and suppressing angiogenesis. Molecular Carcinogenesis. 56(5). 1395–1404. 37 indexed citations
15.
Liu, Xiujun, Yanbo Zheng, Yi Li, Shuying Wu, & Yong‐Su Zhen. (2014). A Multifunctional Drug Combination Shows Highly Potent Therapeutic Efficacy against Human Cancer Xenografts in Athymic Mice. PLoS ONE. 9(12). e115790–e115790. 7 indexed citations
16.
Wang, Weiqin, et al.. (2013). Clinicopathologic characteristics of prefibrotic–early primary myelofibrosis in Chinese patients. Human Pathology. 45(3). 498–503. 5 indexed citations
17.
Zheng, Yanbo, Jianhua Gong, Yi Li, & Yong‐Su Zhen. (2012). [Inhibition of tumor cell invasion and induction of apoptosis by ubenimex].. PubMed. 47(12). 1593–8. 1 indexed citations
18.
Tao, Zhihua, Mo Shen, Yanbo Zheng, et al.. (2010). PCA3 gene expression in prostate cancer tissue in a Chinese population: Quantification by real-time FQ-RT-PCR based on exon 3 of PCA3. Experimental and Molecular Pathology. 89(1). 58–62. 15 indexed citations
19.
Shen, En-Zhi, Yan Lei, Qian Liu, et al.. (2009). Identification and characterization of INMAP, a novel interphase nucleus and mitotic apparatus protein that is involved in spindle formation and cell cycle progression. Experimental Cell Research. 315(7). 1100–1116. 8 indexed citations
20.
Zhang, Xing, et al.. (2005). Effects of anti--tumor drug harringtonine on the proliferation of HeLa cell and its relationship with {\sl CenpB} gene. 21(1). 26–32. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Qunying Wu Breakdown of academic impact, for papers by Dongdong Luo Breakdown of academic impact, for papers by Saeed Salehin Akhand Breakdown of academic impact, for papers by Nathalia Meireles Da Costa Breakdown of academic impact, for papers by Katherine T. Ostapoff Breakdown of academic impact, for papers by Ruoxuan Hei Breakdown of academic impact, for papers by Carolina Hassibe Thomé Breakdown of academic impact, for papers by Stanislav Drápela Breakdown of academic impact, for papers by Rukh Yusuf Breakdown of academic impact, for papers by Loreley Calvet
Rankless by CCL
2026